NGC-Cap demonstrated greater 5-FU exposure than monotherapy capecitabine at a significantly lower dose with a favorable clinical safety profile
NGC-Cap holds potential for improved efficacy in more patients due to an increase in distribution of 5-FU to cancer cells
Phase 1b study final results to be released upon database lock
HANOVER, Md., April 11, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, presented two abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2024, including new Phase 1b data on its Next Generation Capecitabine (NGC-Cap) product. These abstracts are available in the Publications section of Processa's website.
The NGC-Cap Phase 1b trial evaluated ascending doses of capecitabine when combined with a fixed dose of PCS6422 in patients with advanced, relapsed, or refractory progressive gastrointestinal cancer. These patients had to relapse from or fail all other treatments. NGC-Cap demonstrated greater 5-FU (5-fluorouracil) exposure and lower fluoro-beta-alanine (FBAL) exposure with a better or similar side effect profile compared with monotherapy capecitabine.
"The most recent data for the Phase 1b NGC-Cap study presented at AACR highlight NGC-Cap's ability to distribute more 5-FU to cancer cells with 5-10 times greater systemic exposure than when capecitabine is administered alone. As expected with a higher systemic exposure, there was a greater incidence of adverse events with NGC-Cap. However, these adverse events were less dose limiting than seen with other 5-FU metabolites," stated David Young, PharmD, Ph.D., President of Research and Development at Processa. "This Phase 1b study is ongoing due to continued patient response and we plan to release final trial data once the database is locked. Given we have identified the recommended Phase 2 doses and the maximum tolerated dose, we look forward to advancing NGC-Cap into a Phase 2 trial in breast cancer later this year. As agreed to with the FDA, our data in past and ongoing studies will be used to support the breast cancer Phase 2 trial, which streamlines the regulatory path for NCG-Cap."
The poster presentation, titled "Next generation capecitabine (NGC-Cap) in Phase 1b trial significantly increases 5-FU exposure while improving safety profile compared to capecitabine," reported the following more recent findings:
18 patients were enrolled in the first four dose levels of capecitabine in NGC-Cap
The 5-FU exposure, expressed as the area under the 5-FU plasma concentration curve or AUC (geometric mean, CV%), for the two highest doses cohorts of 150 and 225 mg twice-daily NGC-Cap were 4,551 (26.8%) and 6,889 (41.4%) ng-hr/ml, respectively, which is approximately 5-10 times the AUC (0-inf) of 698 (33%) previously reported for a larger dose of approximately 2,250 mg twice-daily of monotherapy capecitabine (Reigner 1998)
Similarly, the 5-FU maximum plasma concentrations (Cmax) for these two cohorts were greater at 1.5 times the Cmax of monotherapy capecitabine
As expected, with the greater 5-FU exposure for all the NGC-Cap cohorts, the incidence of anabolite related side effects was also greater than monotherapy treatment, suggesting that more drug was distributed to duplicating cancer cells and normal cells
The extremely low FBAL catabolite formation and exposure across all NGC-Cap doses resulted in the incidence of catabolite related side effects to be less with only one patient having Grade 1 hand-foot-syndrome, an FBAL related side effect often requiring dose modifications
In addition, Processa presented a second abstract at AACR titled "Application of phase 1 and pre-clinical data to assist in determining the optimal dosage regimen for cancer drugs using the principles of Project Optimus." This abstract briefly describes the U.S. Food and Drug Administration's (FDA) Project Optimus Initiative and draft optimal dosage regimen (ODR) guidance, which requires an ODR justified by a dose-ranging efficacy and safety study, as opposed to a maximum tolerated dose approach. Processa provided preclinical and Phase 1 oncology study examples to demonstrate how the exposure-response relationships for safety and efficacy can provide the recommended dose range to define and justify the optimal dosage regimen in an efficacy-safety study, in a pivotal study, and for FDA approval. The abstract also noted that Project Optimus may require alterations to the design, analysis, and interpretation of clinical trials for cancer drugs compared with what has been done in the past.
About Capecitabine Administered with PCS6422 (NGC-Cap)
NGC-Cap combines the administration of PCS6422, the Company's irreversible dihydropyrimidine dehydrogenase (DPD) enzyme inhibitor, with the administration of low doses of the commonly used chemotherapy capecitabine.
Capecitabine is the oral form of 5-FU and, along with 5-FU, is among the most widely used chemotherapy drugs, particularly for the treatment of solid tumors. When metabolized (after oral ingestion) it becomes 5-FU in the body, which, in turn, metabolizes to molecules called anabolites that actively kill duplicating cells, such as cancer cells, and to molecules called catabolites that only cause side effects. The presence of the DPD enzyme plays an integral role in the undesirable conversion of 5-FU to catabolites.
PCS6422 irreversibly inhibits DPD. PCS6422 is neither toxic nor active as a single agent in animals at comparable dose levels. However, when administered in combination with capecitabine or 5-FU, PCS6422 decreases the metabolism of 5-FU to the catabolites that only cause side effects, allowing more of the 5-FU to distribute to cancer cells.
NGC-Cap 表現出比單一療法卡培他濱更大的5-FU暴露量,劑量明顯降低,臨床安全性良好
由於 5-FU 向癌細胞的分佈增加,NGC-Cap 有可能提高更多患者的療效
1b期研究的最終結果將在數據庫鎖定後公佈
馬里蘭州漢諾威,2024年4月11日(GLOBE NEWSWIRE)——專注於開發具有更高療效和安全性的下一代化療藥物的臨床階段製藥公司Processa Pharmicals, Inc.(納斯達克股票代碼:PCSA)(“Processa” 或 “公司”)在2024年美國癌症研究協會(AACR)年會上提交了兩份摘要,包括有關其下一代Cap的1b期新數據依他濱(NGC-Cap)產品。這些摘要可在Processa網站的 “出版物” 部分找到。
NGC-Cap 1b 期試驗評估了在晚期、復發或難治性進行性胃腸道癌患者中與固定劑量的 PCS6422 聯合使用時卡培他濱的上升劑量。這些患者不得不從所有其他治療中復發或失敗。與單一療法卡培他濱相比,NGC-Cap 表現出更大的5-FU(5-氟尿嘧啶)暴露量和更低的氟β-丙氨酸(FBAL)暴露量,副作用更好或相似。
“在AACR上公佈的1b期NGC-Cap研究的最新數據突顯了NGC-Cap能夠向癌細胞分配更多的5-FU,其全身暴露量是單獨使用卡培他濱時的5-10倍。正如預期的那樣,隨着全身暴露量的增加,NGC-Cap 的不良事件發生率更高。但是,這些不良事件的劑量限制低於其他5-FU代謝物的劑量限制。” Processa研發總裁PharmD博士戴維·楊說。“由於患者持續的反應,這項1b期研究正在進行中,我們計劃在數據庫鎖定後發佈最終的試驗數據。鑑於我們已經確定了推薦的2期劑量和最大耐受劑量,我們期待在今年晚些時候將NGC-Cap推進到乳腺癌的2期試驗。根據與美國食品藥品管理局達成的協議,我們在過去和正在進行的研究中的數據將用於支持乳腺癌2期試驗,該試驗簡化了NCG-Cap的監管路徑。”
標題爲 “與卡培他濱相比,1b期試驗中的下一代卡培他濱(NGC-Cap)顯著增加了5-FU的暴露量,同時提高了安全性” 的海報展示報告了以下最新發現:
18 名患者入組 NGC-Cap 中卡培他濱的前四劑量水平
在每天兩次 150 和 225 mg 的最高劑量隊列中,以 5-FU 血漿濃度曲線或 AUC(幾何平均值,CV%)下的面積表示的 5-FU 暴露量分別爲 4,551 (26.8%) 和 6,889 (41.4%) ng-hr/ml,大約是先前報告的 698 (33%) AUC (0-inf) 的 5-10 倍更大劑量的單一療法卡培他濱,約爲2,250毫克(Reigner 1998)
同樣,這兩個隊列的5-FU最大血漿濃度(Cmax)更高,是單一療法卡培他濱Cmax的1.5倍
正如預期的那樣,隨着所有NGC-Cap隊列的5-FU暴露量增加,合成代謝物相關副作用的發生率也高於單一療法,這表明分配了更多的藥物用於複製癌細胞和正常細胞
在所有 NGC-Cap 劑量中,FBAL 分解代謝物的形成和暴露量極低,導致分解代謝物相關副作用的發生率降低,只有一名患者患有 1 級手足綜合徵,這是一種與 FBAL 相關的副作用,通常需要調整劑量
此外,Processa在AACR上發表了第二份摘要,標題爲 “應用第一階段和臨床前數據,以利用擎天柱計劃的原則幫助確定抗癌藥物的最佳劑量方案”。本摘要簡要描述了美國食品藥品監督管理局(FDA)的擎天柱計劃和最佳劑量方案(ODR)指南草案,該指南要求ODR以劑量範圍療效和安全性研究爲依據,而不是最大耐受劑量方法。Processa提供了臨床前和1期腫瘤學研究示例,以證明安全性和有效性的暴露-反應關係如何提供推薦劑量範圍,以定義和論證療效安全性研究、關鍵研究以及FDA批准的最佳劑量方案。摘要還指出,與過去相比,擎天柱計劃可能需要對抗癌藥物臨床試驗的設計、分析和解釋進行更改。
關於使用 PCS6422(NGC-Cap)給藥的卡培他濱
NGC-Cap 將該公司不可逆的二氫嘧啶脫氫酶 (DPD) 酶抑制劑 PCS6422 的給藥與低劑量的常用化療卡培他濱相結合。
卡培他濱是5-FU的口服形式,與5-FU一樣,是最廣泛使用的化療藥物之一,特別是用於治療實體瘤。當代謝(口服攝入後),它在體內變成5-FU,進而代謝成稱爲合成石的分子,這些分子會主動殺死癌細胞等重複細胞,並代謝成只會引起副作用的稱爲分解代謝物的分子。DPD 酶的存在在 5-FU 向分解石的不良轉化中起着不可或缺的作用。
PCS6422 不可逆地抑制 DPD。在同等劑量水平下,PCS6422 作爲單一藥物對動物既沒有毒性也沒有活性。但是,當與卡培他濱或5-FU聯合使用時,PCS6422 會降低 5-FU 對分解代謝物的代謝,只會產生副作用,從而允許更多的 5-FU 分配給癌細胞。